论文部分内容阅读
目的探讨卵巢交界性肿瘤(BOT)及Ⅰ期上皮性卵巢癌(EOC)的临床病理特征。方法卵巢交界性肿瘤患者(85例,BOT组)和Ⅰ期上皮性卵巢癌患者(58例,EOC组),回顾性分析比较两组患者的临床病理特征。结果 BOT组患者的发病年龄、绝经患者例数、有恶性肿瘤家族史例数均低于EOC组,比较差异有统计学意义(P<0.05)。术前阴道彩色超声检查提示EOC组肿物实性部分明显大于BOT组,两组间血清学肿瘤标记物(CA125、CA199、CP2、CEA)阳性率差异无统计学意义(P>0.05),但在CP2升高的患者中,EOC组CP2值升高幅度显著高于BOT组。结论卵巢交界性肿瘤及Ⅰ期上皮性卵巢癌的临床病理特征虽十分相似,但两者的发病年龄、绝经与否、超声检查提示的卵巢肿物实性部分大小、血清学肿瘤标记物的升高幅度以及组织病理类型均有区别,应熟悉掌握这些病理特征,便于对两种疾病进行鉴别诊断。
Objective To investigate the clinicopathological features of borderline ovarian tumor (BOT) and stage Ⅰ epithelial ovarian cancer (EOC). Methods The clinicopathological features of two groups of patients were retrospectively analyzed in patients with borderline ovarian tumor (85 cases, BOT group) and stage Ⅰ epithelial ovarian cancer (58 cases, EOC group). Results The age of onset, the number of menopause patients and the family history of malignant tumors in BOT group were all lower than those in EOC group (P <0.05). Preoperative vaginal color ultrasound examination showed that the solid part of EOC group was significantly larger than that of BOT group. There was no significant difference in the positive rates of serum tumor markers (CA125, CA199, CP2, CEA) between the two groups (P> 0.05) In patients with elevated CP2, the increase in CP2 was significantly higher in the EOC group than in the BOT group. Conclusions Although the clinicopathological features of borderline ovarian tumors and stage I epithelial ovarian cancer are similar, the age of onset, menopause or not, the real part of the size of ovarian tumor that is echocardiography, the increase of serum tumor markers High-amplitude and histopathological types are different, should be familiar with these pathological features, to facilitate the differential diagnosis of the two diseases.